# Johnson & Johnson

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/johnson-johnson
Canonical HTML page: https://getyourbrief.com/entity/johnson-johnson

## Timeline

- **2026-Q4**: Data Readout — Anticipated top-line data from the Phase 3 VERIFY clinical trial.
- **2026-07-27**: $5.5B Settlement Announced — J&J proposes a global settlement to resolve around 76,000 pending ovarian cancer talc lawsuits, contingent on 95% claimant approval.
- **2026-03-18**: Q4 Earnings — Scheduled announcement of quarterly financial results and pipeline update.
- **2026-03-18**: Quarterly Earnings — Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
- **2026-03-12**: BofA Price Target Hike — Bank of America increases price target, highlighting R&D productivity and MedTech growth.
- **2026-03-12**: BofA Target Increase — Bank of America raises price target based on pharmaceutical and MedTech pipeline strength.
- **2026-03-10**: Institutional Rebalancing — Richard Bernstein Advisors and Rathbones Group PLC report reduced holdings in JNJ.
- **2026-03-07**: Fast-Track Approval — USFDA grants approval for Tecvayli-Darzalex combination via fast-track voucher program.
- **2026-03-07**: Fast-Track Approval — FDA approves Tecvayli-Darzalex combination for blood cancer treatment.
- **2026-03-05**: 12-Month High — JNJ shares reach a new yearly peak following FDA approval for multiple myeloma combo.
- **2026-03-05**: FDA Approval & 12-Month High — JNJ receives FDA approval for multiple myeloma combo and stock hits a yearly peak.
- **2026-02-25**: Institutional Exit Revealed — 13F filings reveal a $170 million divestment by a major institutional fund.
- **2026-02-25**: Institutional Exit — SEC filings reveal a $170 million position liquidation by a major fund.
- **2026-02**: TGA Approval — Australian regulatory body approves the Virtual Nodule Clinic for clinical use.
- **2026-01-20**: 120% Gain Milestone — PTGX stock reaches a 120% gain milestone from its 52-week low.

## Recent coverage (20 stories, network-wide)

### 27 of 287 Applicants Win $12M in Colorado Opioid Prevention Grants
2026-08-02 19:24:44 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 1

Colorado’s $12M opioid grant round, awarded to 27 organizations, will bolster youth treatment, prison re-entry support, and a rural behavioral health workforce—key gaps in the state’s healthcare delivery system. The highly competitive process drew 287 applications, highlighting the severe need for prevention infrastructure.
Full story: https://gethealthbrief.com/story/colorado-opioid-settlement-grants-healthcare-workforce

### Colorado’s $12M Opioid Grant Signals Ongoing Settlement Costs for Pharma
2026-08-02 19:24:34 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 1

Colorado’s distribution of $12 million to 27 groups from opioid settlement funds is the latest reminder of pharma’s enduring financial and reputational liabilities. The grants, part of a broader $700M+ state settlement, fuel prevention programs while underscoring that litigation costs continue to ripple through the industry.
Full story: https://getbiobrief.com/story/colorado-opioid-settlement-pharma-liability-costs

### J&J's $5.5B Talc Settlement: A Litigation Endgame with 95% Approval Hurdle
2026-07-28 14:40:10 · Sector: legal · Sentiment: Negative · Impact: 7/10 · Sources: 3

The $5.5B proposal to resolve 76,000 ovarian cancer talc lawsuits represents a strategic retreat for J&J, contingent on 95% claimant approval and following failed bankruptcy attempts.
Full story: https://getlegalbrief.com/story/jnj-5-5b-talc-settlement-legal-analysis

### J&J's $5.5B Talc Payout: Ovarian Cancer Claims and Consumer Safety Shift
2026-07-28 14:40:04 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 3

The settlement highlights decades of health concerns over talc's link to ovarian cancer, prompting J&J to switch to cornstarch and underscoring ongoing consumer trust issues.
Full story: https://gethealthbrief.com/story/jnj-talc-cancer-settlement-health-impact

### J&J Clears $5.5B Talc Overhang: Refocusing on $85B Pharma Pipeline
2026-07-28 14:39:57 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 3

The settlement removes a major litigation distraction, allowing Johnson & Johnson to redirect resources toward its core pharmaceutical and medtech segments, which generate $85B in annual revenue.
Full story: https://getbiobrief.com/story/jnj-talc-settlement-pharma-outlook

### Over 500 Tylenol suits revived: Prenatal care guidelines under microscope
2026-07-25 19:57:02 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 2

The legal reinstatement of Tylenol-autism lawsuits pressures healthcare providers to reconcile conflicting evidence on acetaminophen safety in pregnancy, potentially altering clinical guidance, patient counseling, and EHR decision support.
Full story: https://gethealthbrief.com/story/tylenol-autism-lawsuits-revived-health

### 500+ Tylenol suits revived: $10B risk for Kenvue and OTC pharma
2026-07-25 19:56:51 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2

The 2nd Circuit ruling revives mass tort litigation linking prenatal acetaminophen to autism, exposing Kenvue and retailers to billions in potential liability. The decision hinges on admissibility of novel scientific evidence, challenging Daubert standards and regulatory orthodoxy.
Full story: https://getbiobrief.com/story/tylenol-autism-lawsuits-revived-bio

### J&J’s $100B Revenue Runway: How Next-Gen Drugs Are Plugging the Stelara Gap
2026-07-20 00:11:51 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 2

J&J’s Q2 2026 earnings beat underscores a successful pivot away from Stelara’s $10B peak. New oncology and immunology drugs are powering growth, with full-year revenue now expected to top $100B. For healthcare stakeholders, this signals pipeline resilience and a defensive stock offering amid sector headwinds.
Full story: https://gethealthbrief.com/story/jnj-100b-pharma-pipeline-stelara-gap-health

### IHE vs IXJ: 0.39% vs 0.41% Fees — Which Healthcare ETF Wins?
2026-07-19 06:02:54 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The iShares U.S. Pharmaceuticals ETF (IHE) and iShares Global Healthcare ETF (IXJ) differ in expense ratios (0.39% vs 0.41%), AUM ($1.4B vs $4.1B), and diversification (56 vs 110 holdings). For finance professionals, the 0.02% fee gap may tip the scales for cost-conscious portfolios, but liquidity and global exposure often justify IXJ's slightly higher expense.
Full story: https://getfinancebrief.com/story/ihe-ixj-healthcare-etf-fee-comparison

### Dividend Kings: Defensive Strategies for a Volatile 2026 Market
2026-03-17 11:43:10 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

As the market enters March 2026, investors are increasingly turning to 'Dividend Kings'—companies with over 50 consecutive years of dividend increases—as a defensive hedge against lingering volatility. This briefing analyzes the top three picks for the month: Procter & Gamble, Johnson & Johnson, and Coca-Cola, highlighting their resilience and compounding potential.
Full story: https://getfinancebrief.com/story/dividend-kings-top-picks-march-2026

### Protagonist Therapeutics Braces for Q1 Earnings Amid Pipeline Milestones
2026-03-17 07:33:39 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Full story: https://getbiobrief.com/story/protagonist-therapeutics-verbund-earnings-preview-2026

### Protagonist Therapeutics Eyes Pivotal Q4 Results Amid Oral Peptide Expansion
2026-03-17 07:33:05 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protagonist Therapeutics (PTGX) is scheduled to release its quarterly earnings on Wednesday, March 18, 2026, with investors focused on the commercialization path for rusfertide and the Phase 3 progress of its oral IL-23 receptor antagonist, icotrokinra. The results will provide a critical update on the company's transition from a clinical-stage biotech to a potential commercial powerhouse in the immunology and hematology sectors.
Full story: https://gethealthbrief.com/story/protagonist-therapeutics-q4-earnings-preview-2026

### BofA Bullish on Johnson & Johnson as Pipeline Momentum Drives Target Hike
2026-03-12 08:12:14 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Bank of America has raised its price target for Johnson & Johnson, citing robust growth in the company's pharmaceutical and MedTech pipelines. The upgrade follows a series of FDA approvals and a strategic pivot toward high-margin innovative medicine after the Kenvue spinoff.
Full story: https://getfinancebrief.com/story/bofa-raises-jnj-price-target-pipeline-growth

### BofA Bullish on Johnson & Johnson as Pipeline Momentum Accelerates
2026-03-12 08:11:42 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Bank of America has raised its price target for Johnson & Johnson, citing a robust outlook for the company's Innovative Medicine and MedTech divisions. The upgrade reflects growing confidence in JNJ's oncology pipeline and its ability to navigate upcoming patent expirations for key assets.
Full story: https://getbiobrief.com/story/bofa-jnj-price-target-pipeline-growth

### BofA Lifts Johnson & Johnson Price Target on Robust Pipeline Momentum
2026-03-12 08:11:39 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Bank of America has raised its price target for Johnson & Johnson (JNJ), citing a strengthened outlook for the company's pharmaceutical and MedTech pipelines. The upgrade reflects growing investor confidence in JNJ's post-Kenvue strategy, which prioritizes high-margin innovation in oncology, immunology, and surgical robotics.
Full story: https://gethealthbrief.com/story/bofa-raises-jnj-price-target-pipeline-growth

### Global Minimally Invasive Surgical Market Set for 7% CAGR Through 2034
2026-03-11 23:18:20 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

A new DelveInsight report projects a steady 7% CAGR for the minimally invasive surgical devices (MISD) market through 2034, driven by technological leaps in robotics and a global shift toward outpatient care. This expansion reflects a broader healthcare transition prioritizing reduced recovery times and improved clinical outcomes over traditional open surgeries.
Full story: https://gethealthbrief.com/story/minimally-invasive-surgical-market-growth-2034

### Legend Biotech and Core Molding Unveil 2025 Results Amid Sector Divergence
2026-03-10 13:51:20 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Legend Biotech and Core Molding Technologies released their full-year 2025 financial results, highlighting a period of strategic expansion and operational resilience. While Legend Biotech continues to scale its CAR-T therapy footprint, Core Molding demonstrated steady performance in the industrial manufacturing sector.
Full story: https://getfinancebrief.com/story/legend-biotech-core-molding-2025-earnings-analysis

### Legend Biotech Reports Robust 2025 Growth Driven by Carvykti Scaling
2026-03-10 13:50:46 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Legend Biotech (LEGN) has announced its fourth-quarter and full-year 2025 financial results, showcasing a significant surge in net trade sales for its CAR-T therapy, Carvykti. The company continues to expand its manufacturing footprint and advance its pipeline in solid tumors, solidifying its position as a leader in the cell therapy market.
Full story: https://getbiobrief.com/story/legend-biotech-q4-2025-results-carvykti-growth

### Optellum Secures TGA Approval for AI Lung Cancer Solution in Australia
2026-02-27 02:36:24 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 3

Optellum has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) for its AI-driven lung nodule management platform. The approval enables the deployment of the Virtual Nodule Clinic to help Australian clinicians identify and treat early-stage lung cancer more effectively.
Full story: https://getbiobrief.com/story/optellum-tga-approval-lung-nodule-ai-australia

### Protagonist Therapeutics Surges 120% as Major Fund Discloses $170M Exit
2026-02-25 21:54:31 · Sector: startups · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Protagonist Therapeutics has seen its stock price more than double following clinical breakthroughs in its oral peptide portfolio, yet a major institutional investor has liquidated a $170 million position. This tactical exit highlights the tension between clinical optimism and institutional profit-taking as the company nears critical Phase 3 milestones.
Full story: https://getstartupbrief.com/story/protagonist-therapeutics-120-percent-surge-170-million-exit

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.